Target
$48.07 → $47.53
Current stock research snapshot · 7/31/26 26 days old
TWSTTwist Bioscience
Investment conviction●●○○○2 of 5 · current snapshot
Research target$47.53Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/31/26
Market cap$5.32BSnapshot value · 7/31/26
Research history
See all TWST changes ↗What changed
Healthspan WATCH — no moat data. Aug earnings could be catalyst. $101 > $95 entry_high — above entry range. NEEDS_MORE_D
Twist Bioscience Q3 FY2026 earnings (Aug 2026); synthetic biology/oligo synthesis demand; NGS target enrichment; biopharma antibody discovery; data storage
Thesis breaks if growth slips below ~15% (FY25 +20.3% -> H1 FY26 +18.1%) extending the path to profitability, enzymatic synthesis (DNA Script/Ansa) solves >300bp error rates to match silicon, biopharma insourcing cuts top-customer concentration, or IDT/Danaher out-invests in synthesis. (vault 2026-08)
Neutral — No investor/analyst mentions of the company found. [X search Aug 2026]
Snapshot · 7/31/26🟡 Mixed · ins-$27.4M · 13F 13+/12-×0.5 · short↓0.21
Snapshot · 7/31/26Timestamped research update
Deep research update
751 words · Updated Aug 2, 2026 · 3 sources
Research in development: this latest 751-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Twist Bioscience manufactures synthetic DNA using a proprietary silicon-based platform that miniaturizes chemical DNA synthesis onto a semiconductor chip. Each chip writes over 1,000,000 oligonucleotides up to 500 bases in parallel, reducing chemical usage by 99.8% vs. traditional plate-based synthesis. Products: synthetic genes, gene fragments, oligo pools, DNA libraries, NGS sample preparation tools, and antibody discovery services (Biopharma segment).
FY2025 (ended Sep 30, 2025): $376.6M revenue (+20.3% YoY), gross margin 50.7% (up from 42.6% FY2024, 36.6% FY2023). H1 FY2026: $214.4M (+18.1% YoY). Net loss $(77.7M) FY2025, rapidly narrowing from $(208.7M) in FY2024. Cash + investments: $232M. ~59.8M diluted shares. Market cap: ~$5.5B at $91.55 (Aug 2, 2026). All financials from SEC 10-K (filed Nov 17, 2025) and 10-Q (filed May 4, 2026).
TWST controls the highest-throughput, lowest-cost DNA synthesis platform at commercial scale. Every gene therapy, every CRISPR edit, every antibody campaign starts with synthesized DNA. As healthspan biotech scales from 100s to 10,000s of programs, the demand for DNA synthesis scales linearly with each program's design-build-test cycles. TWST's silicon platform is the picks-and-shovels bottleneck feeding the entire synthetic biology value chain.
- Silicon platform writes >1M oligos per chip (mobile-phone-sized) at up to 500bp — 99.8% less chemical volume per gene vs. plate synthesis (10-K Item 1, p. 3)
- FY2025 revenue $376.6M, gross margin at 50.7% — GM expansion of +810bps YoY, indicating operating leverage as platform scales (10-K, Consolidated Statements of Operations)
- 200+ issued/allowed patents + 250+ pending applications worldwide as of Sep 30, 2025 — broad IP moat around silicon-based DNA synthesis (10-K, p. 91 R&D team description)
- H1 FY2026 revenue $214.4M (+18.1% YoY) — growth decelerating slightly from 20.3% in FY2025, but sequential Q2 at $110.7M (10-Q filed May 4, 2026)
- Repeat customer revenue: 99% in FY2025 — extremely sticky once integrated into workflows (10-K, Management's Discussion)
- Revenue by geography: Americas ~33%, EMEA ~30%, APAC ~7% — still early in international penetration (10-K, Revenue by Geography table)
Silicon-based DNA synthesis at commercial scale. The quantitative moat has three layers: (1) Manufacturing throughput — 1M oligos per chip vs. ~384-1,536 per conventional plate, a ~1,000× parallelism advantage; (2) Cost crossover — estimated $0.02-0.03/base vs. $0.05-0.10/base conventional, enabled by 99.8% chemical reduction; (3) Workflow switching cost — 99% repeat customer rate means researchers build experimental protocols around TWST's API, oligo pool formats, and gene synthesis specifications. Competitors (IDT/Danaher, GenScript, Thermo Fisher) use conventional phosphoramidite chemistry at lower parallelism. Switching cost estimate: $15-50K per lab to re-validate oligo pools and gene synthesis from an alternative provider (3-6 month requalification cycle for regulated workflows).
- Still unprofitable: Net loss $(77.7M) FY2025, $(74.5M) H1 FY2026. Revenue growth at 18-19% must accelerate or opex must compress further to reach breakeven. Running ~2 years of cash at current burn rate ($183M cash / ~$80M annual burn)
- Growth deceleration: FY2025 +20.3% → H1 FY2026 +18.1%. If growth slips below 15%, the path to profitability extends significantly
- Enzymatic synthesis disruption: DNA Script, Ansa Biotechnologies, and others are developing enzyme-based DNA synthesis that could eventually match silicon on length and cost — if they solve >300bp error rates
- Customer concentration risk: Top customers in biopharma; a shift in R&D budgets or insourcing of synthesis by large pharma could pressure revenue
- Insider selling: Frequent Form 4 filings (multiple per month in June-July 2026) — while likely 10b5-1 plans, the volume bears monitoring
- Competitive response from Danaher/IDT: IDT could invest in higher-throughput synthesis or acquire an enzymatic synthesis startup to compete directly
- What is the revenue split between NGS tools (lower margin, commodity) vs. synthetic biology/antibody discovery (higher margin, differentiated)? The margin trajectory depends on mix shift toward higher-value products
- When does TWST reach operating breakeven? Consensus likely FY2027-FY2028, but needs sustained 20%+ revenue growth + GM expansion
- Is the Biopharma segment (antibody discovery) gaining real traction, or is it still primarily a synthetic biology tools company?
- How defensible is the silicon IP if a deep-pocketed competitor (Danaher, Thermo) decides to replicate the approach?
INTACT — DNA synthesis is a genuine healthspan bottleneck with a durable silicon-based moat. Gross margin expansion to >50% demonstrates real operating leverage. Key risk is growth trajectory: 18-19% is healthy but must not decelerate further. Watch for Q3 FY2026 results (due ~Aug 2026) for revenue acceleration signal.
Primary and supporting material
Sources
3 sources preserved from the latest qualified research update.